Melbourne, Australia; 6 June 2011: Global regenerative medicine company, Mesoblast Limited (ASX: MSB; OTC ADR: MBLTY), today announced that its Chief Executive, Silviu Itescu, will present at the Goldman Sachs 32nd Annual Global Healthcare Conference in the United States. Mesoblast joins Resmed and Ramsay Healthcare as the only Australian companies participating in the global investor forum.
Professor Itescu is due to speak at the conference in Los Angeles on Wednesday 8 June at 8:40 a.m. US PT (Thursday, 9 June at 1:40 a.m. in Melbourne).
To access a live audio webcast of the presentation you may use the link:
http://cc.talkpoint.com/gold006/060711a_lr/?entity=67_IKXHJB0. An archived version of the webcast will be available until 15 June 2011.
About Mesoblast Limited
Mesoblast Limited (ASX: MSB; OTC ADR: MBLTY) is a world leader in the development, manufacture, and commercialization of biologic products for the broad field of regenerative medicine. Mesoblast has the worldwide exclusive rights to a series of patents and technologies developed over more than 10 years relating to the identification, extraction, culture and uses of adult Mesenchymal Precursor Cells (MPCs). More information - www.mesoblast.com.
For further information, please contact:
Julie Meldrum
Corporate Communications Director
T: + 61 (0) 3 9639 6036
E: julie.meldrum@mesoblast.com
| © Copyright 1996-2019 irasia.com Ltd. All rights reserved. |
|
DISCLAIMER: irasia.com Ltd makes no guarantee as to the accuracy or completeness of any
information provided on this website. Under no circumstances shall irasia.com Ltd be liable
for damages resulting from the use of the information provided on this website.
TRADEMARK & COPYRIGHT: All intellectual property rights subsisting in the contents of this website belong to irasia.com Ltd or have been lawfully licensed to irasia.com Ltd for use on this website. All rights under applicable laws are hereby reserved. Reproduction of this website in whole or in part without the express written permission of irasia.com Ltd is strictly prohibited. TERMS OF USE: Please read the Terms of Use governing the use of our website. |